Advertisement
Advertisement

AQST

AQST logo

Aquestive Therapeutics, Inc. Common Stock

4.32
USD
Sponsored
-0.67
-13.53%
Jun 25, 11:10 UTC -4
Open

AQST Earnings Reports

Positive Surprise Ratio

AQST beat 16 of 32 last estimates.

50%

Next Report

Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$11.65M
/
-$0.10
Implied change from Q1 26 (Revenue/ EPS)
-19.37%
/
+42.86%
Implied change from Q2 25 (Revenue/ EPS)
+16.45%
/
-28.57%

Aquestive Therapeutics, Inc. Common Stock earnings per share and revenue

On May 13, 2026, AQST reported earnings of -0.07 USD per share (EPS) for Q1 26, beating the estimate of -0.13 USD, resulting in a 49.96% surprise. Revenue reached 14.45 million, compared to an expected 11.11 million, with a 29.98% difference. The market reacted with a +1.20% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 11.65 million USD, implying an increase of 42.86% EPS, and decrease of -19.37% in Revenue from the last quarter.
FAQ
For Q1 2026, Aquestive Therapeutics, Inc. Common Stock reported EPS of -$0.07, beating estimates by 49.96%, and revenue of $14.45M, 29.98% above expectations.
The stock price moved up 1.2%, changed from $4.18 before the earnings release to $4.23 the day after.
The next earning report is scheduled for Aug 10, 2026.
Based on 8 analysts, Aquestive Therapeutics, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $11.65M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement